Ozoralizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ozoralizumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
Formula C1682H2608N472O538S12
Molar mass 38.43 kg/mol
 NYesY (what is this?)  (verify)

Ozoralizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.

Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to Eddingpharm.

References[edit]